Welcome to our Breakthrough Challenge fundraising page! We are participating to show our support for the Breakthrough Challenge and Penn Medicine’s Abramson Cancer Center.

Please join us by registering today for the Breakthrough Challenge and be a part of our team. This is your opportunity to have an important role in the new chapter in the story of cancer treatment and do something challenging and rewarding in so many ways. 

Our fundraising efforts will support Penn Medicine's Abramson Cancer Center. We are fueling the research that will deliver breakthroughs!

Make your tax-deductible donation today and take the first step toward helping us achieve our goal.

Your contribution to the Breakthrough Challenge may be eligible for an employer matching donation. Please check with your employer's benefit program for more details.

Building on Penn's leadership in Translational Medicine and investigator initiated clinical trials established over the past two decades, CCI is focused on coordinated interdisciplinary approaches for the discovery and development of core platform technologies for personalized cell and gene based therapies in cancer, autoimmune disease, infectious disease, and organ and bone marrow transplantation. CCI interacts with a coalition of investigators in nearly all departments and centers in the Perelman School of Medicine; driving clinical translation of novel and investigational immune-based therapies. CCI will fuse clinical investigators and scientists within the Abramson Cancer Center, the Institute for Immunology, the Center for AIDS research, the Cardiovascular Institute and the Center for Orphan Disease Research and Therapy, and the program in novel biotherapeutics within the Institute of Translational Medicine and Therapeutics. The CCI mission is to accelerate and synergize efforts that quickly transition fundamental immunobiology research into the clinic; bringing value to the University of Pennsylvania and it's faculty beyond existing department, center, and institutional structures.